Progenitor Cell Therapy to Treat Acute Myocardial Infarction: The Promise of High-Dose Autologous CD34 Bone Marrow Mononuclear CellsReportar como inadecuado




Progenitor Cell Therapy to Treat Acute Myocardial Infarction: The Promise of High-Dose Autologous CD34 Bone Marrow Mononuclear Cells - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Stem Cells InternationalVolume 2013 2013, Article ID 658480, 8 pages

Review Article

Emory University School of Medicine, Division of Cardiology, 319 Woodruff Memorial Research Building, 1639 Pierce Drive, Suite 319, Atlanta, GA 30322, USA

Emory Clinical Cardiovascular Research Institute, 1462 Clifton Road NE, Suite 506, Atlanta, GA 30322, USA

Received 19 October 2012; Revised 18 March 2013; Accepted 21 March 2013

Academic Editor: Leonard M. Eisenberg

Copyright © 2013 Joseph C. Poole and Arshed A. Quyyumi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

ST elevation myocardial infarction STEMI is associated with an increased risk for congestive heart failure and long-term mortality despite the widespread use of thrombolysis and catheter-based revascularization. The need for improved post-STEMI therapies has led to a surge of novel therapeutics, especially regenerative approaches using autologous mononuclear cells. Indeed, the past decade has been marked by a number of human trials studying the safety and efficacy of progenitor cell delivery in the post-STEMI setting. While a variety of cell types and delivery techniques have been utilized, directed therapy to the infarct-related artery has been the most widely used approach. From over 1300 subjects randomized in these studies, there is sufficient evidence to conclude that cell therapy after STEMI is uniformly safe, while the efficacy of this intervention for improving outcomes is less clear. Recent meta-analyses have highlighted the importance of both timing of cell delivery, as well as the type, quantity, and mobility of delivered cells as determinants of response. Here, we show the case in which higher doses of CD34

cells, which are more potent in terms of their migratory capacity, offer the best hope for preserving cardiac function following STEMI.





Autor: Joseph C. Poole and Arshed A. Quyyumi

Fuente: https://www.hindawi.com/



DESCARGAR PDF




Documentos relacionados